Cost-effectiveness analysis of therapeutic options for chronic hepatitis C genotype 3 infected patients

References

• Deuffic-Burban S, Deltenre P, Buti M, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology. 2012;143:974–985.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Duberg AS, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat. 2014;21(Suppl 1):60–89.
   PubMed Web of Science ®Google Scholar
• Vietri J, Prajapati G, El Khoury AC. The burden of hepatitis C in Europe from the patients’ perspective: a survey in 5 countries. BMC Gastroenterol. 2013;13:16.
   PubMed Web of Science ®Google Scholar
• Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138(2):513–521.
   PubMed Web of Science ®Google Scholar
• Nevens F, Colle I, Michielsen P, et al. Resource use and cost of hepatitis C-related care. Eur J Gastroenterol Hepatol. 2012;24:1191–1198.
   PubMed Web of Science ®Google Scholar
• Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology. 2013;144(7):1450–1455.
   PubMed Web of Science ®Google Scholar
• Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677–684.
   PubMed Web of Science ®Google Scholar
• Cardoso A-C, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol. 2010;52:652–657.
   PubMed Web of Science ®Google Scholar
• Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59(1):318–327.
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology (Baltimore, MD). 2014;60(1):98–105.
   PubMed Web of Science ®Google Scholar
• Shah SR, Patel K, Marcellin P, et al. Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3. Clin Gastroenterol Hepatol. 2011;9(8):688–693.
   PubMed Web of Science ®Google Scholar
• Pawlotsky J-M. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146(5):1176–1192.
   PubMed Web of Science ®Google Scholar
• Buti M, Esteban R. Hepatitis C virus genotype 3: a genotype that is not ‘easy-to-treat’. Expert Rev Gastroenterol Hepatol. 2015;9(3):375–385.
   PubMed Web of Science ®Google Scholar
• Ferenci P. Treatment of hepatitis C in difficult-to-treat patients. Nat Rev Gastroenterol Hepatol. 2015 May;12(5):284–292.
   PubMed Web of Science ®Google Scholar
• Ramos-Sánchez MDC, Martín-Gil FJ. [Changes in the distribution of hepatitis C virus (HCV) genotypes over the 1999-2010 period in northern Valladolid, Spain]. Rev Esp Salud Publica. 2011;85:227–230.
   PubMed Web of Science ®Google Scholar
• EASL. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199–236.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127–1135.
   PubMed Web of Science ®Google Scholar
• Blázquez-Pérez A, San Miguel R, Mar J. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. Pharmacoeconomics. 2013;31(10):919–931.
   PubMed Web of Science ®Google Scholar
• San Miguel R, Gimeno-Ballester V, Blázquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut. 2015;64(8):1277–1288.
   PubMed Web of Science ®Google Scholar
• Sacristan JA, Oliva J, Del Llano J. What is an efficient health technology in Spain? Gaceta Sanitaria. 2002;4:334–343.
   Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–1887.
   PubMed Web of Science ®Google Scholar
• Poynard T, Colombo M, Bruix J, et al. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology. 2009;136(5):1618–1628.
   PubMed Web of Science ®Google Scholar
• Foster GR, Pianko S, Brown A, et al. Efficacy of sofosbuvir plus ribavirin with or without peginterferon-alfa in patients with hepatitis C virus genotype 3 infection and treatment-experienced patients with cirrhosis and hepatitis C virus genotype 2 infection. Gastroenterology. 2015;149(6):1462–1470.
   PubMed Web of Science ®Google Scholar
• Welzel TM, Ferenci P, Petersen J, et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program. 50th annual meeting of the European association for the Study of the Liver. Viena; 2015.
   Google Scholar
• European Medicines Agency. Summary of product characteristics: Daklinza. 2014. [cited 2015 Nov 12]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf
   Google Scholar
• European Medicines Agency. Summary of product characteristics: Sovaldi. 2015. [cited 2015 Nov 12]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/. WC500160597.pdf
   Google Scholar
• General Spanish Council of Pharmacists. BOT database of pharmaceutical prices. 2015 [cited 2015 Nov 12]. Available from: http://www.portalfarma.com/Paginas/default.aspx
   Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975–982.
   PubMed Web of Science ®Google Scholar
• Hay JW, Smeeding J, Carroll NV, et al. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR drug cost task force report - part I. Value Health. 2010;13:3–7.
   PubMed Web of Science ®Google Scholar
• Evon DM, Edwards A, Straub B, et al. Adherence to all-oral HCV treatment in patients with substance and alcohol use disorders. Hepatology. 2015;62:731A.
   Google Scholar
• Younossi ZM, Stepanova M, Henry L, et al. Adherence to interferon (IFN) and ribavirin (RBV)-free regimens for treatment of chronic hepatitis C (CH-C): are there any associations with clinical and patient-reported outcomes (PROs)? Am J Gastroenterol. 2015;110:S895.
   Google Scholar
• Hauser G, Awad T, Brok J, et al. Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C. Cochrane Database Syst Rev. 2014;2:CD005441.
   PubMed Web of Science ®Google Scholar
• Townsend R, McEwan P, Kim R, et al. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C. Value Health. 2011;14(8):1068–1077.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463–472.
   PubMed Web of Science ®Google Scholar
• Buti M, Casado MA, Fosbrook L, et al. [Cost effectiveness of the treatment of chronic hepatitis C with interferon-alpha]. Gastroenterol Hepatol. 1998;21(4):161–168.
   PubMedGoogle Scholar
• Buti M, Casado MA, Fosbrook L, et al. Financial impact of two different ways of evaluating early virological response to peginterferon-alpha-2b plus ribavirin therapy in treatment-naive patients with chronic hepatitis C virus genotype 1. Pharmacoeconomics. 2005;23(10):1043–1055.
   PubMed Web of Science ®Google Scholar
• San Miguel R, Mar J, Cabasés JM, et al. Cost-effectiveness analysis of therapeutic strategies for patients with chronic hepatitis C previously not responding to interferon. Aliment Pharmacol Ther. 2003;17:765–773.
   PubMed Web of Science ®Google Scholar
• Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut. 2006;55(9):1332–1338.
   PubMed Web of Science ®Google Scholar
• Cure S, Bianic F, Gavart S, et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ. 2014;17(1):65–76.
   PubMedGoogle Scholar
• Cure S, Bianic F, Gavart S, et al. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients. J Med Econ. 2014;17(1):77–87.
   PubMedGoogle Scholar
• Kieran J, Mushtaq H, Bergin C, et al. Demographics and health-state utilities of irish patients with hepatitis C infection; use of the 5-level EQ-5D questionnaire. Value Health. 2012;15(7):A528.
   Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;346:f1049.
   PubMed Web of Science ®Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3. Med Decis Making. 2012;32(5):690–700.
   PubMed Web of Science ®Google Scholar
• Planas R, Ballesté B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40(5):823–830.
   PubMed Web of Science ®Google Scholar
• Salomon JA, Weinstein MC, Hammitt JK, et al. Empirically calibrated model of hepatitis C virus infection in the United States. Am J Epidemiol. 2002;156(8):761–773.
   PubMed Web of Science ®Google Scholar
• Registro Español de Trasplante Hepático. Memoria de resultados. 2010 [cited 2015 Sep 24]. Available from: http://www.ont.es/infesp/Paginas/RegistroHepatico.aspx
   Google Scholar
• Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Intern Med. 1997;127(10):855–865.
   PubMed Web of Science ®Google Scholar
• López Bastida J, Oliva J, Antoñanzas F, et al. [A proposed guideline for economic evaluation of health technologies]. Gac Sanit. 2010;24(2):154–170.
   PubMed Web of Science ®Google Scholar
• Briggs AH, Weinstein MC, Fenwick EAL, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–6. Value Health. 2012;15(6):835–842.
   PubMed Web of Science ®Google Scholar
• Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
   Google Scholar
• van de Vooren K, Curto A, Garattini L. Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness? Eur J Health Econ. 2015;16(4):341–345.
   PubMed Web of Science ®Google Scholar
• Probst A, Dang T, Bochud M, et al. Role of hepatitis C virus genotype 3 in liver fibrosis progression–a systematic review and meta-analysis. J Viral Hepat. 2011;18:745–759.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221.
   PubMed Web of Science ®Google Scholar
• Leroy V, Angus PW, Bronowicki J-P, et al. All-oral treatment with daclatasvir (DCV) plus sofosbuvir (SOF) plus ribavirin (RBV) for 12 or 16 weeks in HCV genotype (GT) 3-infected patients with advanced fibrosis or cirrhosis: the ALLY-3+ phase 3 study. Hepatology. 2015;62:1380A–81.
   Google Scholar